Li Yaxiong

Li Yaxiong


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2021 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
TXTao Xiong
Tao Xiong
LPLei Pu
Lei Pu
YMYuan-Feng Ma
Yuan-Feng Ma
YZYun-Long Zhu
Yun-Long Zhu
HLHua Li
Hua Li
LYLi Yaxiong
Li Yaxiong
Background: Atrial fibrillation (AF) is associated with adverse events after cardiac surgery. Multiple studies have reported that posterior pericardiotomy (PP) may be effective for preventing AF after coronary artery bypass grafting (CABG), but some conflicting results have been reported and the quality of evidence from previous meta-analyses has been limited. The present study aimed to systematically evaluate the safety and efficacy of PP for preventing AF after CABG in adults. Methods: We conducted a quantitative meta-analysis of randomized controlled trials (RCTs) published before May 31, 2021. The primary outcome was AF after CABG under cardiopulmonary bypass. Secondary outcomes included early pericardial effusion, late pericardial effusion, pericardial tamponade, pleural effusion, length of hospital stay, length of intensive care unit (ICU) stay, pulmonary complications, intra-aortic balloon pump use, revision surgery for bleeding, and mortality. Results: Ten RCTs with 1829 patients (910 in the PP group and 919 in the control group) were included in the current meta-analysis. The incidence of AF was 10.3% (94/910) in the PP group and 25.7% (236/919) in the control group. A random-effects model indicated that incidence of AF after CABG significantly lower in the PP group than in the control group (risk ratio = 0.45, 95% confidence interval 0.29–0.64, P < 0.0001). PP also effectively reduced the post-CABG occurrence of early pericardial effusion (RR = 0.28, 95% CI 0.15–0.50; P < 0.05), late pericardial effusion (RR = 0.06, 95% CI 0.02–0.16; P < 0.05), and pericardial tamponade (RR = 0.08, 95% CI 0.02–0.33; P < 0.05) as well as the length of ICU stay (weighted mean difference [WMD] = 0.91,95% CI 0.57–1.24; P < 0.05), while increasing the occurrence pleural effusion (RR = 1.51, 95% CI 1.19–1.92; P < 0.05). No significant differences length of hospital stay (WMD = − 0.45, 95% CI − 2.44 to 1.54, P = 0.66), pulmonary complications (RR = 0.99, 95% CI 0.71–1.39, P = 0.97), revision surgery for bleeding (RR = 0.84, 95% CI 0.43–1.63, P = 0.60), use of IABP (RR = 1, 95% CI 0.61–1.65, P = 1.0), or death (RR = 0.45, 95% CI 0.07–3.03, P = 0.41) were observed between the PP and control groups. Conclusions: PP may be a safe, effective, and economical method for preventing AF after CABG in adult patients.

21 March 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
LPLei Pu
Lei Pu
MMMingyao Meng
Mingyao Meng
JWJian Wu
Jian Wu
JZJing Zhang
Jing Zhang
ZHZongliu Hou
Zongliu Hou
LYLi Yaxiong
Li Yaxiong
The success of developing cardiovascular tissue engineering (CTE) grafts greatly needs a readily available cell substitute for endothelial and interstitial cells. Perinatal annexes have been proposed as a valuable source of mesenchymal stem cells (MSCs) for tissue engineering and regenerative medicine. The objective of the present study is to evaluate the potential of human Wharton’s jelly MSCs (WJ-MSCs) and amniotic membrane MSCs (AM-MSCs) as a seeding cell in CTE and cardiovascular regenerative medicine. WJ-MSCs/AM-MSCs were isolated and characterized in vitro according to their morphology, proliferation, self-renewal, phenotype, and multipotency. More importantly, the characteristics of hemocompatibility, extracellular matrix deposition, and gene expression and viability of both MSCs were investigated. Fibroblast-like human WJ-MSCs and AM-MSCs were successfully isolated and positively expressed the characteristic markers CD73, CD90, and CD105 but were negative for CD34, CD45, and HLA-DR. Both MSCs shared trilineage differentiation toward the adipogenic, osteogenic, and chondrogenic lineages. The proliferative and self-renewal capacity of WJ-MSCs was significantly higher than that of AM-MSCs (P < 0.001). WJ-MSCs provided comparable properties of antiplatelet adhesion and did not activate the coagulation cascade to endothelial cells. However, aggregated platelets were visualized on the surface of AM-MSCs-derived cell sheets and the intrinsic pathway was activated. Furthermore, WJ-MSCs have superior properties of collagen deposition and higher viability than AM-MSCs during cell sheet formation. This study highlights that WJ-MSCs could act as a functional substitute of endothelial and interstitial cells, which could serve as an appealing and practical single-cell source for CTE and regenerative therapy.

28 February 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
TXTao Xiong
Tao Xiong
SHShen Han
Shen Han
LPLei Pu
Lei Pu
TZTian-Chen Zhang
Tian-Chen Zhang
XZXu Zhan
Xu Zhan
LYLi Yaxiong
Li Yaxiong
Aim: The purpose of this study was to identify potential diagnostic markers for aortic valve calcification (AVC) and to investigate the function of immune cell infiltration in this disease. Methods: The AVC data sets were obtained from the Gene Expression Omnibus. The identification of differentially expressed genes (DEGs) and the performance of functional correlation analysis were carried out using the R software. To explore hub genes related to AVC, a protein–protein interaction network was created. Diagnostic markers for AVC were then screened and verified using the least absolute shrinkage and selection operator, logistic regression, support vector machine-recursive feature elimination algorithms, and hub genes. The infiltration of immune cells into AVC tissues was evaluated using CIBERSORT, and the correlation between diagnostic markers and infiltrating immune cells was analyzed. Finally, the Connectivity Map database was used to forecast the candidate small molecule drugs that might be used as prospective medications to treat AVC. Results: A total of 337 DEGs were screened. The DEGs that were discovered were mostly related with atherosclerosis and arteriosclerotic cardiovascular disease, according to the analyses. Gene sets involved in the chemokine signaling pathway and cytokine–cytokine receptor interaction were differently active in AVC compared with control. As the diagnostic marker for AVC, fibronectin 1 (FN1) (area the curve = 0.958) was discovered. Immune cell infiltration analysis revealed that the AVC process may be mediated by naïve B cells, memory B cells, plasma cells, activated natural killer cells, monocytes, and macrophages M0. Additionally, FN1 expression was associated with memory B cells, M0 macrophages, activated mast cells, resting mast cells, monocytes, and activated natural killer cells. AVC may be reversed with the use of yohimbic acid, the most promising small molecule discovered so far. Conclusion: FN1 can be used as a diagnostic marker for AVC. It has been shown that immune cell infiltration is important in the onset and progression of AVC, which may benefit in the improvement of AVC diagnosis and treatment.

8 March 2017 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
LPLei Pu
Lei Pu
JWJian Wu
Jian Wu
XPXingna Pan
Xingna Pan
ZHZongliu Hou
Zongliu Hou
JZJing Zhang
Jing Zhang
LJLihong Jiang
Lihong Jiang

1 June 2018 in Toxicon
Verified
Journal Article
Closed access
RORose Ombati
Rose Ombati
YWYunfei Wang
Yunfei Wang
CDCanwei Du
Canwei Du
XLXiancui Lu
Xiancui Lu
BLBowen Li
Bowen Li
Ren LaiRen Lai
Ren Lai

14 December 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
TXTao Xiong
Tao Xiong
LPLei Pu
Lei Pu
YMYuan-Feng Ma
Yuan-Feng Ma
YZYun-Long Zhu
Yun-Long Zhu
XCXu Cui
Xu Cui
LYLi Yaxiong
Li Yaxiong
Objectives: Hypothermic cardiopulmonary bypass (HCPB) has been used successfully in cardiac surgery for more than half a century, although adverse effects have been reported with its use. Many studies on temperature management during CPB published to date have shown that normothermic CPB (NCPB) provides more benefits to children undergoing cardiac surgery. The present meta-analysis investigated the effect of NCPB on clinical outcomes based on results of randomized controlled trials and observational studies on pediatric cardiac surgery.Methods: Databases such as PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Clinical Trials.gov were searched from inception to May 2021 to identify relevant studies published in English.Results: The present meta-analysis included 13 studies characterizing a total of 837 pediatric patients. The random effects model exhibited that the NCPB group had reduced revision for postoperative bleeding [odds ratio (OR): 0.11; 95% confidence interval (CI): 0.01–0.89; I2 = 0%, P = 0.04], serum lactate 2–4 h after CPB (mean difference: −0.60; 95% CI: −1.09 to −0.11; I2 = 82%, P = 0.02), serum creatinemia 24 h after CPB (mean difference: −2.73; 95% CI: −5.06 to −0.39; I2 = 83%, P = 0.02), serum creatinemia 48 h after CPB (mean difference: −2.08; 95% CI: −2.78 to −1.39; I2 = 0%, P < 0.05), CPB time (mean difference: −19.10, 95% CI: −32.03 to −6.18; I2 = 96%, P = 0.04), and major adverse events (OR: 0.37; 95% CI: 0.15–0.93; Z = 2.12, P = 0.03) after simple congenital surgery compared with the HCPB group.Conclusion: NCPB is as safe as HCPB in pediatric congenital heart surgery. Moreover, NCPB provides more advantages than HCPB in simple congenital heart surgery.